This FDA pre-IND clearance removes a key regulatory de-risking event for PT00114, making the IND submission timeline (Q4 2026) the next catalyst. However, the company's penny stock status, limited trading liquidity, and going-concern warning mean any positive price reaction may be muted by dilution risk from future financings. Monitor for capital raise announcements alongside the IND timeline.
Price Chart
Executive Summary
Protagenic Therapeutics received written FDA pre-IND feedback for its lead candidate PT00114 in generalized anxiety disorder. The FDA raised no objections to the planned Phase 1 program design, CMC, or nonclinical packages, clearing a path for an IND submission by end of 2026 with first patient dosing targeted for H1 2027. This is a positive regulatory milestone for a pre-revenue clinical-stage biotech, but the company faces substantial capital needs and going-concern risk as disclosed in its filings.
Key Facts
- FDA provided written pre-IND responses for PT00114 in generalized anxiety disorder (GAD).
- FDA identified no clinical hold issues and raised no objection to the planned three-part Phase 1 program design.
- FDA indicated the proposed CMC, nonclinical, and potency/comparability packages appear reasonable to support an IND submission.
- Company plans to submit the IND before the end of 2026 and target first patient dosing in H1 2027.
- PT00114 has completed prior Phase 1 SAD/MAD studies outside the US with no serious adverse events reported.
- No new medicine has been approved specifically for GAD by the FDA in nearly two decades.
Financial Impact
No financial figures disclosed. Company is pre-revenue with substantial doubt about its ability to continue as a going concern.
Risk Factors
- FDA pre-IND advice is non-binding; FDA may still impose a clinical hold or request additional data upon IND review.
- Company has a history of losses and substantial doubt about its ability to continue as a going concern, requiring significant additional capital.
- Results from prior ex-US healthy volunteer studies may not be predictive of US clinical trial results in GAD patients.
- Limited trading liquidity and penny stock status on OTCQB create price volatility and potential for dilution from future financings.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-039410 |
| Exhibit: ex99-1.htm | 0001493152-26-039410 |
| Document: 0001493152-26-039410-index-headers.html | 0001493152-26-039410 |
| Document: 0001493152-26-039410-index.html | 0001493152-26-039410 |
| Document: 0001493152-26-039410.txt | 0001493152-26-039410 |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers